Ez-PAVE
2026
Ez-PAVE: Ezetimibe Combination Therapy for Patients With Atherosclerotic Cardiovascular Disease, prespecified second randomisation
In patients with atherosclerotic cardiovascular disease, initial statin-ezetimibe combination therapy did not reduce the 3-year composite of cardiovascular death, myocardial infarction, stroke, revascularisation or hospitalisation for unstable angina compared with statin monotherapy.
Résultat
Efficacité: Cardiovascular outcomes within 3 yearshazard ratio 1,07 (IC à 95 % 0,83-1,37) · P = 0,596
En dessous de 1 en faveur de initial statin-ezetimibe combination therapy, au-dessus de 1 en faveur de statin monotherapy.
- Différence absolue
- 0,6 points
La différence absolue est dérivée des taux d’événements.
Également rapporté: Median LDL-C during follow-up was 53 mg/dL (interquartile range 45-62) vs 62 mg/dL (interquartile range 53-74) with intensive targeting, and 63 mg/dL (interquartile range 55-73) vs 70 mg/dL (interquartile range 62-81) with conventional targeting. The safety end points were similar between the groups.
- Sous-thème
- Ezetimibe combination
- Schéma
- Open-label 2-by-2 factorial randomised trial in Korea (Yonsei University). First randomisation: LDL-C target below 55 versus below 70 mg/dL. The prespecified second randomisation, presented here: statin-ezetimibe combination versus statin monotherapy
- Inclus
- 3 048 patients
- Source
- Lee SH, Byun YS, et al. Circulation. 2026; published online 7 November.doi 10.1161/CIRCULATIONAHA.126.083811
Discussion et critique
Starting with statin-ezetimibe combination therapy lowered LDL-C during follow-up under both targeting strategies but did not reduce the primary composite endpoint compared with statin monotherapy. The composite includes any revascularisation and hospitalisation for unstable angina, so softer components may weigh on the total, and the abstract does not break the endpoint down into its components. Follow-up is three years, which may be too short to show a difference in hard outcomes from a modest gap in LDL-C. The abstract reports safety only as similar between groups and gives no figures.